Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Patent
1997-06-13
2000-09-05
Page, Thurman K.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
424451, 424468, 424470, 424475, 424474, 530300, 530379, A61K 914, A61K 952, A61K 3818
Patent
active
061139475
ABSTRACT:
NGF microencapsulation compositions having controlled release characteristics, preferably with increased stability, for the NGF component, particularly human recombinant NGF ("rhNGF") are provided that yield enhanced stability of NGF for use in promoting nerve cell growth, repair, survival, differentiation, maturation or function. Methods for making and using such compositions are also provided.
REFERENCES:
patent: 3773919 (1973-11-01), Boswell
patent: 4485045 (1984-11-01), Regen
patent: 4544545 (1985-10-01), Ryan et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5288622 (1994-02-01), Gray et al.
patent: 5488099 (1996-01-01), Persson et al.
patent: 5589167 (1996-12-01), Cleland et al.
Angeletti et al., "Nerve Growth Factor From Mouse Submaxillary Gland: Amino Acid Sequence" Proc. Natl. Acad. Sci. USA 68(10): 2417-2420 (1971).
Apfel et al., "Nerve Growth Factor Prevents Experimental Cisplatin Neuropathy" Ann. Neurol. 31: 76-80 (1992).
Apfel et al., "Nerve Growth Factor Prevents Toxic Neuropathy in Mice" Annals of Neurology 29(1):87-90. Jan. 1991.
Berman et al., "Age-Related Changes in Regional Cerebral Blood Flow and Behavior in Sprague-Dawley Rats" Neurobiol. Aging 9: 691-696 (1988).
Bigl et al., "The Nucleus basalis of Meynert during ageing and in dementing neuropsychiatric disorders" Brain Cholinergic Systems, Steriade and Biesold, Oxford:Oxford University Press pp. 364-386 (1990).
Bothwell et al., "Dissociation Equilibrium Constant of .beta. Nerve Growth Factor" The Journal of Biological Chemistry 252(23): 8532-8536 (Dec. 10, 1977).
Cleland et al., "Stable Formulations of Recombinant Human Growth Hormone and Interferon-gamma for Microencapsulation in Biodegradable Microspheres" Pharm. Res. 13: 1464-1475 (1996).
Canova-Davis et al., "Amino-terminal serine to glycine post-translational modification observed in nerve growth factor biosynthesized in Chinese hamster ovary cells" Peptides (Proceedings of the Thirteenth American Peptide Symposium Jun. 20-25, 1993), Hodges and Smith, Leiden The Netherlands:ESCOM pp. 230-231.
Connolly et al., "Pit Formation and Rapid Changes in Surface Morphology of Sympathetic Neurons in Response to Nerve Growth Factor" Journal of Cell Biology 90: 176-180 (Jul. 1981).
Davies, "The Neurochemistry of Alzheimer's Disease and Senile Dementia" Med. Res. Rev. 3: 221-236 (1983).
De Young et al., "Temperature and pH Dependence of Recombinant Human Nerve Growth Factor Dimer Dissociation" Biophys. Journal 66(2): A401 (Feb. 1994).
Eppstein et al., "Biological Activity of Liposome-Encapsulated Murine Interferon Gama Is Mediated by Cell Membrane Receptor" Proc. Natl. Acad. Sci. 82(11): 3688-3692 (1985).
Fischer et al., "NGF Improves Spatial Memory in Aged Rodents as a Function of Age" J. Neurosci. 11(7): 1889-1906 (1991).
Greene, "A Quantitative Bioassay for Nerve Growth Factor (NGF) Activity Employing a Clonal Pheochromocytoma Cell Line" Brain Research 133: 350-353 (1977).
Halegoua et al., "Nerve Growth Factor Mediates Phosphorylation of Specific Proteins" Cell 22: 571-581 (Nov. 1980).
Hefti, Franz, "Nerve Growth Factor Promotes Survival of Septal Cholinergic Neurons After Fimbrial Transections" J. of Neuroscience 6(8): 2155-2162 (Aug. 1986).
Holland et al., "Nerve Growth Factor in Different Crystal Forms Displays Structural Flexibility and Reveals Zinc Binding Sites" J. Mol. Biol. 239: 385-400 (1994).
Hwang et al., "Hepatic uptake and degradation of unilamellar shingomyelin/cholesterol liposomes: a kinetic study" Proc. Natl. Acad. Sci. 77: 4030-4034 (1980).
Johnson et al., "A Month-Long Effect From a Single Injection of Microencapsulated Human Growth Hormone" Nature Medicine 2: 795-799 (1996).
Koliatsos et al., "Human Nerve Growth Factor Prevents Degeneration of Basal Forebrain Cholinergic Neurons in Primates" Ann. Neurol. 30: 831-840 (1991).
Koliatsos et al., "Recombinant Human Nerve Growth Factor Prevents Retrograde Degeneration of Axotomized Basal Forebrain Cholinergic Neurons in the Rat" Exp. Neurol. 112: 161-173 (1991).
Korsching, Sigrun, "The role of nerve growth factor in the CNS" TINS pp. 570-573 (Nov./Dec. 1986).
Langer, "Controlled Release of Macromolecules" Chem. Tech. 12: 98-105 (1982).
Langer et al., "Biocompatibibility of Polymeric Delivery Systems for Macromolecules" J. Biomed. Mater. Res. 15: 267-277 (1981).
Lotfi et al., "Cerebral Hemodynamic and Metabolic Effects of Chronic Alcoholism" Cerebrovasc. and Brain Metab. Rev. 1: 2-25 (1989).
McDonald et al., "New Protein Fold Revealed by a 2.3-A Resolution Crystal Structure of Nerve Growth Factor" Nature 354: 411-414 (1991).
Moore et al., "The Use of Hybrid Molecules in a Study of the Equilibrium Between Nerve Growth Factor Monomers and Dimers" Neurobiology 5: 369-381 (1975).
Mumenthaler et al., "Feasibility Study on Spray-Drying Protein Pharmaceuticals: Recombinant Human Growth Hormone and Tissue-Type Plasminogen Activator" Pharm. Res. 11: 12-20 (1994).
Petty et al., "The Effect of Systemically Administered Recombinant Human Nerve Growth Factor in Healthy Human Subjects" Ann. Neurol. 36: 244-246 (1994).
Schmelzer et al., "Biochemical Characterization of Recombinant Human Nerve Growth Factor" Journal of Neurochemistry 59(5): 1675-1683 (1992).
Scott, et al., "Isolation and nucleotide sequence of a cDNA encoding the precursor of mouse nerve growth factor" Nature 302: 538-540 (1983).
Shih et al., "Mutagenesis Identifies Amino-terminal Residues of Nerve Growth Factor Necessary for Trk Receptor Binding and Biological Activity" Journal of Biological Chemistry 269: 27679-27686 (1994).
Sidman et al., "Controlled Release of Macromolecules and Pharmaceuticals from Synthetic Polypeptides Based on Glutamic Acid" Biopolymers 22(1): 547-556 (1983).
Skaper et al., "Maintenance by Nerve Growth Factor of the Intracellular Sodium Environment in Spinal Sensory and Sympathetic Ganglionic Cells" Brain Research 197: 379-389 (1980).
Thoenen et al., "Physiology of Nerve Growth Factor" Physiological Reviews 60 (4): 1284-1335 (Oct. 1980).
Tiercy et al., "Early Changes in the Synthesis of Nuclear and Cytoplasmic Proteins Are Induced by Nerve Growth Factor in Differentiating Rat PC12 Cells" Journal of Cell Biology 103 (6): 2367-2378 (Dec. 1986).
Timm et al., "Comparitive Equilibrium Denaturation Studies of the Neurotrophins: Nerve Growth Factor, Brain-derived Neurotrophic Factor, Neurotrophin 3, and Neurotrophin 4/5" Biochemistry 33: 4667-4676 (1994).
Timm et al., "Equilibrium Denaturation Studies of Mouse .beta.-nerve Growth Factor" Protein Science I; 236-244 (1992).
Tuszynski et al., "Recombinant Human Nerve Growth Factor Infusions Prevent Cholinergic Neuronal Degeneration in the Adult Primate Brain" Ann. Neurol. 30: 625-636 (1991).
Ullrich et al., "Human .beta.-nerve Growth Factor Gene Sequence Highly Homologous to That of Mouse" Nature 303: 821-825 (Jun. 1983).
Ullrich et al., "Sequence Homology of Human and Mouse B-NGF Subunit Genes" Symp. on Quan. Biol. 48: 435-442 (1983).
Urfer et al., "The Binding Epitopes of Neurotrophin-3 to its Receptors trkC and gp75 and the Design of a Multifunctional Human Neurotrophin" The EMBO Journal 13(24): 5896-5909 (1994).
Urfer et al., "Specificity Determinants in Neurotropin-3 and Design of Nerve Growth Factor-Based trkC Agonists by Changing Central B-Strand Bundle Residues to Their Neurotrophin-3 Analogs" Biochemistry 36: 4775-4781 (1997).
Williams, "Exogenous Nerve Growth Factor Stimulates Choline Acetyltransferase Activity in Aging Fischer 344 Male Rats" Nuerobiol. Aging 12: 39-46 (1991).
Yu et al., "Increased Phosphorylation of Specific Nuclear Proteins in Superior Cervical Ganglia and PC12 Cells in Response to Nerve Growth Factor" Journal of Biological Chemistry 255(21): 10481-10492 (Nov. 10, 1980).
Cleland and Duenas, "Controlled Delivery of Nerve Growth Factor for Local Treatment of Neuronal Diseases" Proceed. Intl. Symp. Control. Rel. Bioact. Mater. pp. 823-824 (1997).
Frederickson et al., "Zinc-containing 7s-NGF Complex. Evidence From Histochemistry for Localization in Salivary Secretory Granules" Journal of Histochemistry and Cytochemistry 35(5): 579-583 (1987).
Ross
Cleland Jeffrey L.
Duenas Eileen T.
Lam Xanthe M.
Channavajjala Lakshmi
Genentech Inc.
Page Thurman K.
LandOfFree
Controlled release microencapsulated NGF formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Controlled release microencapsulated NGF formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Controlled release microencapsulated NGF formulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2209462